Advanced Therapeutics

Scope & Guideline

Pioneering interdisciplinary research for tomorrow's health.

Introduction

Welcome to the Advanced Therapeutics information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Advanced Therapeutics, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN-
PublisherWILEY
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationADV THER-GERMANY / Adv. Therap.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Advanced Therapeutics' focuses on innovative therapeutic strategies and advanced drug delivery systems, particularly in the fields of nanomedicine, immunotherapy, and biomaterials. It aims to bridge the gap between laboratory research and clinical applications, advancing therapeutic modalities for various diseases.
  1. Nanomedicine and Targeted Drug Delivery:
    The journal emphasizes the development of nanomedicines that enhance drug delivery efficacy and specificity, targeting diseases such as cancer, diabetes, and infectious diseases through innovative nanoparticle designs.
  2. Immunotherapy and Cancer Treatment:
    A significant focus is on immunotherapy approaches, including the use of vaccines, immune checkpoint inhibitors, and engineered immune cells to combat cancer and enhance immune responses.
  3. Biomaterials and Regenerative Medicine:
    Research on biomaterials for tissue engineering and regenerative medicine is prevalent, exploring how these materials can enhance healing processes and support cellular therapies.
  4. Innovative Therapeutic Modalities:
    The journal covers a wide range of therapeutic strategies, including photothermal and photodynamic therapies, combination therapies, and the utilization of bioengineering techniques to optimize treatment outcomes.
  5. Emerging Technologies in Drug Development:
    Recent advancements in drug delivery technologies, such as hydrogels, microneedles, and smart nanoparticles, are investigated for their potential to improve therapeutic efficacy and patient compliance.
The journal 'Advanced Therapeutics' has identified several emerging themes that are gaining traction in recent publications. These trends reflect the evolving landscape of therapeutic research and the integration of novel technologies in medicine.
  1. Personalized Medicine and AI Integration:
    There is a growing trend toward personalized medicine, utilizing artificial intelligence to optimize treatment plans and drug formulations tailored to individual patient profiles.
  2. Extracellular Vesicles and Nanoparticles:
    Research into extracellular vesicles as delivery systems is on the rise, highlighting their potential in targeted therapy and diagnostics, particularly in cancer and regenerative medicine.
  3. Combination Therapies:
    The investigation of combination therapies that synergistically enhance therapeutic effects is increasingly common, particularly in oncology, where multiple modalities are employed to overcome resistance.
  4. 3D Bioprinting and Tissue Engineering:
    Emerging technologies like 3D bioprinting are gaining attention for their potential to create complex tissue structures for regenerative medicine, offering new avenues for treatment.
  5. Immunomodulatory Therapies:
    There is a heightened focus on immunomodulatory therapies, aiming to harness the body's immune system to fight diseases, particularly cancer and chronic infections.

Declining or Waning

While 'Advanced Therapeutics' continues to explore a broad range of therapeutic innovations, certain themes have shown a decline in prominence over recent years. These waning scopes may reflect shifting research priorities or advancements in other areas.
  1. Traditional Small Molecule Drugs:
    There seems to be a diminishing focus on traditional small molecule drug development, as the field increasingly gravitates towards innovative delivery systems and advanced therapeutic modalities.
  2. Invasive Surgical Techniques:
    Research related to invasive surgical techniques is less frequent, with a growing preference for less invasive, technology-driven approaches such as minimally invasive interventions and nanomedicine.
  3. Conventional Chemotherapy:
    The emphasis on conventional chemotherapy regimens appears to be waning, as the field seeks more targeted and personalized treatment options that minimize side effects and enhance efficacy.
  4. Non-Specific Antimicrobial Treatments:
    The exploration of broad-spectrum antimicrobial treatments is declining in favor of more targeted approaches, including precision medicine and the development of specific immunotherapeutic strategies.
  5. Basic Research without Translational Focus:
    There is a noticeable decrease in studies that do not directly translate into clinical applications, as the journal prioritizes research with clear therapeutic implications.

Similar Journals

Materials Science & Engineering C-Materials for Biological Applications

Advancing biomaterials for a healthier future.
Publisher: ELSEVIERISSN: 0928-4931Frequency: 12 issues/year

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

International Journal of Nanomedicine

Exploring the frontiers of nanotechnology in medicine.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2013Frequency: 1 issue/year

International Journal of Nanomedicine, published by DOVE MEDICAL PRESS LTD, is a leading open access journal dedicated to advancing the field of nanomedicine and its applications in healthcare. Since its establishment in 2006, the journal has grown significantly, now encompassing a wide array of topics including bioengineering, biomaterials, biophysics, drug discovery, and pharmaceutical sciences, and is recognized in Q1 quartiles across major categories like *Nanoscience and Nanotechnology* and *Organic Chemistry*. The journal boasts an impressive standing within the Scopus rankings, with high percentiles across various related fields, making it an invaluable resource for researchers, professionals, and students seeking to stay informed on the latest innovations and developments in nanomedicine. With its commitment to fostering an accessible and collaborative academic environment, the International Journal of Nanomedicine serves as a vital platform for disseminating transformative research that impacts scientific practice and healthcare outcomes globally.

CYTOTECHNOLOGY

Fostering Collaboration: Uniting Experts in the Pursuit of Cytotechnology Excellence.
Publisher: SPRINGERISSN: 0920-9069Frequency: 6 issues/year

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

APL Bioengineering

Exploring New Frontiers in Bioengineering Research
Publisher: AIP PublishingISSN: 2473-2877Frequency: 4 issues/year

APL Bioengineering is a premier open-access journal published by AIP Publishing, dedicated to advancing the field of bioengineering and its interdisciplinary applications. Established in 2017, this journal serves as a vital platform for researchers, professionals, and students interested in the critical intersections of bioengineering, biomaterials, biomedical engineering, and biophysics. With an impressive impact factor and consistent rankings in the Q1 category across multiple domains, including biochemistry and materials science, APL Bioengineering has positioned itself among the top journals in its field. The journal aims to publish innovative original research, comprehensive reviews, and insightful case studies that further the understanding and application of bioengineering principles. Since its inception, APL Bioengineering has fostered a community of thought leaders, providing open access to ensure broad dissemination of knowledge and advancements that underpin the future of biomedical innovation.

VIEW

Uniting Global Scholars in Biomedical Engineering Advancement.
Publisher: WILEYISSN: 2688-3988Frequency: 6 issues/year

VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

DRUG DELIVERY

Pioneering Breakthroughs in Pharmaceutical Sciences
Publisher: TAYLOR & FRANCIS LTDISSN: 1071-7544Frequency: 1 issue/year

DRUG DELIVERY is a premier academic journal published by TAYLOR & FRANCIS LTD, with a steadfast commitment to advancing research in the fields of medicine and pharmaceutical sciences. As an Open Access journal since 2017, it offers unparalleled accessibility to its high-quality content, making it an invaluable resource for researchers, professionals, and students alike. With an impressive 2023 impact factor, it ranks in the Q1 quartile for both Medicine (miscellaneous) and Pharmaceutical Science, evidencing its significant impact within the scientific community. The journal focuses on innovative drug delivery systems, therapeutics, and methodologies that enhance patient care and treatment options. Based in the United Kingdom, it has evolved since its inception in 1993 to create a richly diverse platform for scholarly dialogue and advancements in the pharmaceutical landscape. Researchers looking to stay at the forefront of drug delivery research will find DRUG DELIVERY an essential companion in their pursuits.

Materials

Connecting researchers to the latest breakthroughs in materials technology.
Publisher: MDPIISSN: Frequency: 24 issues/year

Materials is an esteemed journal published by MDPI, dedicated to advancing the fields of Condensed Matter Physics and Materials Science. With its commitment to Open Access since its inception in 2008, the journal has made significant strides in disseminating high-quality research globally, allowing researchers, professionals, and students easy access to cutting-edge studies without financial barriers. Hailing from Switzerland, the journal has shown remarkable growth and prominence, currently ranked in the Q2 quartile in its categories according to the latest assessments, which highlights its impact within the community. As the journal converges its focus from 2008 to 2024, it aims to continually foster a robust exchange of knowledge on innovative materials and their applications, thereby supporting the evolving landscape of science and technology. With an E-ISSN of 1996-1944 and a user-friendly platform, Materials is poised to be a leading choice for scholars eager to contribute to and engage with pioneering research.

CURRENT DRUG TARGETS

Illuminating Pathways in Clinical Biochemistry
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

BIOMATERIALS

Exploring the Frontiers of Biomaterials Science
Publisher: ELSEVIER SCI LTDISSN: 0142-9612Frequency: 36 issues/year

BIOMATERIALS, published by Elsevier Science Ltd, is a premier academic journal dedicated to the interdisciplinary field of biomaterials research. With an impressive impact factor, it ranks in the Q1 quartile across multiple categories including Bioengineering, Biomaterials, and Biophysics, showcasing its significance in advancing scientific knowledge. Established in 1980 and set to converge its discussions through 2025, this journal provides a critical platform for researchers and professionals to disseminate their findings on the development, application, and performance of biomaterials. The journal covers a wide range of topics, from the mechanics of materials to nanotechnology, and is highly regarded with top Scopus rankings in essential categories, including an exceptional position within the 99th percentile for Biophysics. Although not an open access journal, BIOMATERIALS remains vital for students and established researchers alike, ensuring accessibility to groundbreaking research in the field. Engage with cutting-edge studies that pave the way for innovative applications in medicine, engineering, and beyond.

Nano Today

Catalyzing discoveries that shape tomorrow's innovations.
Publisher: ELSEVIER SCI LTDISSN: 1748-0132Frequency: 6 issues/year

Nano Today is a prestigious journal published by ELSEVIER SCI LTD that stands at the forefront of nanoscience and nanotechnology research. With an impact factor that underscores its significance, this journal has achieved remarkable rankings in several key categories as of 2023, including Q1 positions in Bioengineering, Biomedical Engineering, Biotechnology, Materials Science, and Pharmaceutical Science, making it an essential resource for scholars and professionals alike. ISSN 1748-0132 and E-ISSN 1878-044X, the journal serves as a vital platform for disseminating cutting-edge research findings and innovative applications in the field. Although open access options are not available, the journal's rich repository of peer-reviewed articles provides invaluable insights into the latest advancements in nanotechnologies. Based in the Netherlands, Nano Today not only connects a global network of researchers but also propels forward the conversation on the transformative potential of nanomaterials across multiple disciplines. With a commitment to advancing knowledge and fostering innovation, Nano Today is an indispensable tool for academics and practitioners dedicated to pushing the boundaries of scientific exploration.